Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MK2206
DRUG
2 trials
Sponsors
National Taiwan University Hospital
, Centre Leon Berard
Conditions
Diffuse Large B Cell Lymphoma
Non Small Cell Lung Cancer
Phase 1
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
NCT01147211
National Taiwan University Hospital
Non Small Cell Lung Cancer
Start: 2010-09-30
End: 2013-12-31
Target: 21
Updated: 2013-05-03
Phase 2
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Terminated
NCT01466868
Centre Leon Berard
Diffuse Large B Cell Lymphoma
Start: 2011-11-30
End: 2014-06-30
Updated: 2014-07-10
Related Papers
A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.
Journal of Clinical Oncology
2014-05-20
2 citations